or
Remember me
Back
-- Net revenue of $5.5 million -- a decrease of 11% over Q4 2020 -- Vanluven facility received EU-GMP certification allowing VIVO to export cannabis products for sale in Europe and Beacon Medical Germany GmbH received an import license to allow imports of medical cannabis -- Released brick hash as part of VIVO's Cannabis 2.0 product lineup and expect to release a new line of topicals in Q2 2021, VIVO's 9th and 10th product formats, respectively -- Closed an $8 million equity offering in February 2021, including the full exercise of the over-allotment option
A daily snapshot of everything from market open to close.